Search Results

GSK on Wednesday restructured its contract with CureVac to gain access to the biotech’s influenza and COVID-19 programs for $430 million upfront and up to $1.13 billion in future payments.

CureVac N.V. (Nasdaq:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the first quarter of 2024 and provided a business update.

CureVac N.V. today announced that Thaminda Ramanayake has been appointed to the role of Chief Business Officer, effective June 1, 2024.

CureVac N.V. today announced dosing of the first participant in a Phase 2 study of the multivalent seasonal influenza vaccine candidate developed in collaboration with GSK.

CureVac N.V. (Nasdaq:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and The University of Texas MD Anderson Cancer Center today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update.

A court in Germany on Tuesday nullified one of CureVac’s intellectual property rights in a patent case against BioNTech. However, court proceedings involving seven other patent rights will continue.

CureVac N.V. will report financial results, and provide business updates for the fourth quarter and full-year 2023 on Wednesday, April 24, 2024.

CureVac N.V. (Nasdaq:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced interim data from an ongoing Phase 2 part of the combined Phase 1/2 study of its seasonal influenza vaccine candidate, conducted in collaboration with GSK.